Q-omics provides the consensus-scored RPL6P25 profile across patient tissues and cancer cell-line models. RPL6P25 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, RPL6P25 is differentially expressed in 4, with the highest sampling consensus in COAD. Additionally, RPL6P25 RNA expression shows 6,199 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UCEC, COAD, and ACC as cancer lineages where RPL6P25 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL6P25 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL6P25 survival associations across molecular data types. RPL6P25 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL6P25 RNA expression–survival associations across cancer types. High RPL6P25 expression shows unfavorable associations in SARC, ACC, LUAD and ESCA, but favorable associations in UCEC and HNSC. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCEC as the clearest survival context for RPL6P25 RNA expression.
This table summarizes RPL6P25 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPL6P25. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL6P25 shows higher tumor expression in COAD, PRAD, KIRC and KICH. The COAD box plot shows higher RPL6P25 RNA expression in tumor versus normal tissue (log2 FC = +0.194, t-test p = .002).
This table shows molecular features associated with RPL6P25 in patient tissues and cancer cell lines. In patient samples, RPL6P25 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
